Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNTH NASDAQ:HUMA NASDAQ:LENZ NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$36.58+1.0%$30.41$13.36▼$40.16$1.18B1.58425,449 shs45,459 shsHUMAHumacyte$1.74-2.0%$1.70$1.15▼$6.77$274.77M1.894.26 million shs619,876 shsLENZLENZ Therapeutics$41.68-0.4%$40.91$16.53▼$50.40$1.19B0.5364,976 shs162,726 shsPRAXPraxis Precision Medicines$189.87+231.1%$47.61$26.70▼$178.00$3.91B2.62466,580 shs5.72 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%HUMAHumacyte-1.12%+4.73%+15.69%-26.86%-68.95%LENZLENZ Therapeutics+7.86%-13.89%+4.60%+21.06%+59.55%PRAXPraxis Precision Medicines+9.20%+5.64%+41.78%+4.39%-20.40%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNTHDianthus Therapeutics$36.58+1.0%$30.41$13.36▼$40.16$1.18B1.58425,449 shs45,459 shsHUMAHumacyte$1.74-2.0%$1.70$1.15▼$6.77$274.77M1.894.26 million shs619,876 shsLENZLENZ Therapeutics$41.68-0.4%$40.91$16.53▼$50.40$1.19B0.5364,976 shs162,726 shsPRAXPraxis Precision Medicines$189.87+231.1%$47.61$26.70▼$178.00$3.91B2.62466,580 shs5.72 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNTHDianthus Therapeutics+1.86%+4.17%-2.27%+77.89%+31.45%HUMAHumacyte-1.12%+4.73%+15.69%-26.86%-68.95%LENZLENZ Therapeutics+7.86%-13.89%+4.60%+21.06%+59.55%PRAXPraxis Precision Medicines+9.20%+5.64%+41.78%+4.39%-20.40%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNTHDianthus Therapeutics 2.82Moderate Buy$60.8866.44% UpsideHUMAHumacyte 2.63Moderate Buy$8.38382.71% UpsideLENZLENZ Therapeutics 2.67Moderate Buy$52.8026.69% UpsidePRAXPraxis Precision Medicines 2.75Moderate Buy$85.56-54.94% DownsideCurrent Analyst Ratings BreakdownLatest HUMA, DNTH, PRAX, and LENZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025DNTHDianthus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$56.0010/13/2025HUMAHumacyteUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$6.0010/13/2025HUMAHumacyteBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $6.0010/10/2025LENZLENZ TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$67.0010/8/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025HUMAHumacyteWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LENZLENZ TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/30/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/27/2025DNTHDianthus TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNTHDianthus Therapeutics$4.85M242.54N/AN/A$11.91 per share3.07HUMAHumacyte$1.57M175.01N/AN/A($0.41) per share-4.23LENZLENZ TherapeuticsN/AN/AN/AN/A$7.42 per shareN/APRAXPraxis Precision Medicines$8.55M467.46N/AN/A$23.90 per share7.94Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNTHDianthus Therapeutics-$84.97M-$3.25N/AN/AN/A-2,364.56%-34.72%-32.72%11/6/2025 (Estimated)HUMAHumacyte-$148.70M-$0.45N/AN/AN/AN/AN/A-78.26%11/14/2025 (Estimated)LENZLENZ Therapeutics-$49.77M-$1.90N/AN/AN/AN/A-25.63%-24.43%11/5/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)Latest HUMA, DNTH, PRAX, and LENZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025DNTHDianthus Therapeutics-$0.88N/AN/AN/A$0.58 millionN/A11/5/2025Q3 2025LENZLENZ Therapeutics-$0.67N/AN/AN/AN/AN/A11/5/2025Q3 2025PRAXPraxis Precision Medicines-$3.45N/AN/AN/A$0.06 millionN/A8/11/2025Q2 2025HUMAHumacyte-$0.15-$0.24-$0.09-$0.24$0.94 million$0.30 million8/7/2025Q2 2025DNTHDianthus Therapeutics-$0.86-$0.88-$0.02-$0.88$0.87 million$0.19 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/A7/30/2025Q2 2025LENZLENZ Therapeutics-$0.58-$0.53+$0.05-$0.53$5.00 million$5.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNTHDianthus TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ALENZLENZ TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNTHDianthus TherapeuticsN/A13.1213.12HUMAHumacyte2.972.451.93LENZLENZ TherapeuticsN/A20.5420.54PRAXPraxis Precision MedicinesN/A6.316.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNTHDianthus Therapeutics47.53%HUMAHumacyte44.71%LENZLENZ Therapeutics54.32%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipDNTHDianthus Therapeutics8.15%HUMAHumacyte5.10%LENZLENZ Therapeutics6.90%PRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNTHDianthus Therapeutics8032.19 million29.57 millionOptionableHUMAHumacyte150158.37 million150.30 millionOptionableLENZLENZ Therapeutics11028.52 million26.55 millionN/APRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableHUMA, DNTH, PRAX, and LENZ HeadlinesRecent News About These CompaniesPraxis Precision Medicines' movement disorder drug shows promise in trials4 hours ago | reuters.comAberdeen Group plc Acquires 126,153 Shares of Praxis Precision Medicines, Inc. $PRAXOctober 16 at 3:43 AM | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Receives Sell (D-) Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comDid the ReCode Partnership Just Shift Praxis Precision Medicines' (PRAX) Innovation Narrative in Neuroscience?October 8, 2025 | finance.yahoo.comAssessing Praxis Precision Medicines (PRAX) Valuation After Recent Share Price MomentumOctober 8, 2025 | finance.yahoo.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | globenewswire.comReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate UpdateSeptember 30, 2025 | finance.yahoo.comA CT man has to pay $300K+ in fines for insider trading. He got prison too.September 24, 2025 | courant.comCCT man gets 2 months in prison for insider trading scheme that netted $220KSeptember 23, 2025 | msn.comWeston man gets 2 months in prison for insider trading scheme that netted $220KSeptember 23, 2025 | stamfordadvocate.comSAssenagon Asset Management S.A. Raises Position in Praxis Precision Medicines, Inc. $PRAXSeptember 22, 2025 | marketbeat.comJones Trading Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationSeptember 19, 2025 | msn.comJones Trading Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)September 19, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 5% - What's Next?September 18, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $6.71 Million Stock Holdings in Praxis Precision Medicines, Inc. $PRAXSeptember 16, 2025 | marketbeat.comPRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXSeptember 13, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXSeptember 8, 2025 | prnewswire.comPraxis Precision Medicines (PRAX) Has a New Rating from LifeSci CapitalSeptember 6, 2025 | theglobeandmail.comPraxis Precision Medicines to Participate in September Investor ConferencesSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHUMA, DNTH, PRAX, and LENZ Company DescriptionsDianthus Therapeutics NASDAQ:DNTH$36.58 +0.38 (+1.04%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.Humacyte NASDAQ:HUMA$1.74 -0.04 (-1.98%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.LENZ Therapeutics NASDAQ:LENZ$41.68 -0.18 (-0.42%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.Praxis Precision Medicines NASDAQ:PRAX$189.60 +132.25 (+230.61%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Tempus AI Hits $100—Are Shares Due for a Pullback? Vertiv Stock Surges on Strategic CFO Hire and AI Momentum NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
